|5Feb 6, 4:34 PM ET

HedgePath Pharmaceuticals, Inc. 5

5 · HedgePath Pharmaceuticals, Inc. · Filed Feb 6, 2015

Insider Transaction Report

Form 5
Period: 2014-12-31
Hasara Garrison J.
CEO, Secretary & Treasurer
Transactions
  • Award

    Restricted Stock Units

    2014-08-06+3,500,0003,500,000 total
    Common Stock (3,500,000 underlying)
  • Award

    Restricted Stock Units

    2014-08-06+3,500,0003,500,000 total
    Common Stock (3,500,000 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents a right to receive one share of the issuer's common stock.
  • [F2]The restricted stock units were issued to the reporting person on August 6, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan. The restricted stock units will vest on the earlier to occur of (i) September 3, 2016 and (ii) the receipt of written notice of acceptance for the filing of an NDA by the issuer for the its patented formulation of the drug itraconazole, known as SUBATM-Itraconazole, in a particular dose formulation for the treatment of human patients with cancer via oral administration.
  • [F3]The restricted stock units were issued to the reporting person on August 6, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan. The restricted stock units will vest on September 3, 2017.

Documents

1 file
  • 5
    doc5.xmlPrimary

    FORM 5 SUBMISSION